Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib + Trametinib in BRAF V600E+ NSCLC (Chinese patients)
NCT04452877Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2020
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Aug 2020; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04452877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04452877.